ArticleHeart (British Cardiac Society)2006
Cost of cardiovascular diseases in the United Kingdom.
Article in Heart (British Cardiac Society), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07213479 (Feasibility and Acceptability of Remote Home-Based Isometric Exercise and Lifestyle Change for the Management of Hypertension), which is not on this map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility and Acceptability of Remote Home-Based Isometric Exercise and Lifestyle Change for the Management of Hypertension
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 203 citations in OpenAlex.
- Global comparison of the economic costs of coronary heart disease: a systematic review and meta-analysis.BMJ open · 2025Pooled it
- Estimating productivity costs using the friction cost approach in practice: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2016Pooled it
- High-Flow Nasal Oxygen Therapy After Cardiac Surgery: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Trial
- UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study).European archives of psychiatry and clinical neuroscience · 2009Trial
- The Equality Health-CVD intervention: protocol for a feasibility study of a home-based multi-component cardiovascular support intervention.Pilot and feasibility studies · 2026Article
- Article
- Economic burden of cardiovascular disease in the United Kingdom.European heart journal. Quality of care & clinical outcomes · 2025Article
- Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.EClinicalMedicine · 2025Article
- Health care utilization and the associated costs attributable to cardiovascular disease in Ireland: a cross-sectional study.European heart journal. Quality of care & clinical outcomes · 2025Article
- Breaking binary in cardiovascular disease risk prediction.NPJ cardiovascular health · 2025Review
- Pioglitazone and barriers to effective post-stroke comorbidity management in stroke survivors with diabetes.Neurosciences (Riyadh, Saudi Arabia) · 2024Article
- Phenomics and Robust Multiomics Data for Cardiovascular Disease Subtyping.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.PharmacoEconomics · 2023Article
- Integrated approach to cardiovascular disease in people experiencing homelessness: a qualitative study.Open heart · 2023Article
- Change in coronary heart disease hospitalization after chronic disease management: a programme policy in China.Health policy and planning · 2023Article
- Health care costs of cardiovascular disease in China: a machine learning-based cross-sectional study.Frontiers in public health · 2023Article
- Comparing Korea Occupational Safety & Health Agency and National Health Insurance Service's cardio-cerebrovascular diseases risk-assessment tools using data from one hospital's health checkups.Annals of occupational and environmental medicine · 2023Article
- Article
- Price versus clinical guidelines in primary care statin prescribing: a retrospective cohort study and cost simulation model.Journal of the Royal Society of Medicine · 2022Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate the economic burden of cardiovascular disease (CVD) in the United Kingdom, including health and non-healthcare costs, and the proportion of total CVD cost due to coronary heart disease (CHD) and cerebrovascular disease. DESIGN AND
settingPrevalence-based approach to assess CVD-related costs from a societal perspective. PATIENTS: All UK residents in 2004 with CVD (International classification of diseases, 10th revision (ICD-10) codes I00-I99) and subgroups with CHD (ICD-10 codes I20-I25) or cerebrovascular disease (ICD-10 codes I60-I69).
main outcome measuresHealthcare costs were estimated from expenditure on community health and social services, accident and emergency care, hospital care, rehabilitation and drugs. Non-healthcare costs were estimated from data on informal care and from productivity losses arising from morbidity and premature death.
resultsCVD cost the UK economy 29.1 billion pound in 2004, with CHD and cerebrovascular disease accounting for 29% (8.5 billion pound) and 27% (8.0 billion pound) of the total, respectively. The major cost component of CVD was health care, which accounted for 60% of the cost, followed by productivity losses due to mortality and morbidity, accounting for 23%, with the remaining 17% due to informal care-related costs.
conclusionsCVD is a leading public health problem in the UK measured by the economic burden of disease. This study identified the size and main components of that burden, and will help to inform decisions about research priorities and to monitor the impact of policy initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.